Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Enzo Biochem, 4D Path, Proscia, Quest Diagnostics, and More

NEW YORK – Enzo Biochem reported this week that it estimates its revenues for the quarter ending Oct. 31 will meet or exceed $27 million, representing sequential growth of at least 40 percent.

The company also said that Fabian Blank and Peter Clemens have resigned from the board of directors, effective immediately. Both board members were originally nominated by Enzo investor Harbert Discovery Fund. Separately, the company said Mary Tagliaferri has been appointed to the board, effective immediately.

Tagliaferri currently serves as executive clinical fellow and senior vice president at Nektar Therapeutics. She previously served as chief medical officer at Nektar, as well as chief medical officer and chief regulatory officer for Kanglaite-USA, and was cofounder, president, and board member of Bionovo.

4D Path this week announced that the US Food & Drug Administration granted Breakthrough Device Designation for its 4D Q-plasia OncoReader Breast software as a medical device. The solution provides histopathologists with an adjunct technology to improve the diagnostic accuracy of breast cancer features ─ such as its invasiveness and grade ─ solely from digitized histopathology images obtained by biopsies or resections, the firm said.

It "shows great promise in aiding clinical histopathologists to mitigate some of the diagnostic challenges in the current standard of care, particularly those stemming from tumor heterogeneity, thereby improving the diagnostic accuracy," Tathagata Dasgupta, founder and chief technology officer at 4D Path, said in a statement.

DermTech said this week that it has entered into an agreement, effective Nov. 3, with Blue Cross Blue Shield of Illinois for the company’s PLA gene expression test for the early detection of melanoma to be made available to Blue Cross Blue Shield's Commercial PPO and Medicare Advantage membership.  

The test offers significant benefits in early melanoma detection and reduced biopsies of benign lesions, while also reducing overall healthcare costs, the company said.

NASA's Jet Propulsion Laboratory said this week it is collaborating with the National Cancer Institute Consortium for Molecular Characterization of Screen-Detected Lesions (MCL) to digitize a repository of pathology data to make it readily accessible to researchers from across the seven sites of the MCL. The partners will deploy Proscia's Concentriq to serve as the foundational software infrastructure for the initiative.

The UK government said this week it will open two high throughput diagnostic testing laboratories early next year, creating up to 4,000 jobs. When they are operating at full capacity, the testing labs ─ which will be located in Scotland and in Leamington Spa in England ─ are expected to add 600,000 tests per day to the UK's testing capacity.

The laboratories are an important component of the UK’s national infrastructure, its ability to respond to future epidemics, and to add testing capacity for other critical illnesses, including cancers, and cardiovascular and metabolic diseases, the UK government said. The labs will use technologies built by British manufacturers, including for automation, robotics, and consumables.

Interpace Biosciences said this week that it has received notice from the Nasdaq that the firm is in violation of Nasdaq Listing Rule 5250 (c)(1), due to the delay in filing its Form 10-Q for the quarter ended Sept. 30 with the Securities and Exchange Commission. The rule requires that companies file all periodic reports with the SEC in a timely manner. Interpace was provided 60 days to submit its plan to show compliance with the filing requirement. The Nasdaq has the discretion to grant Interpace up to 180 days from the SEC deadline to file the Form 10-Q based on the plan.

Agilent Technologies this week declared a quarterly dividend of $.19 per share, to be paid on Jan. 27, 2021, to shareholders of record as of the close of business on Jan. 5, 2021.

Quest Diagnostics' board of directors this week declared a quarterly dividend of $.56 per share, payable Feb. 3, 2021, to shareholders of record as of Jan. 20, 2021.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.